Nuvation Bio [NUVB] vs Adaptive [ADPT] Detailed Stock Comparison
Nuvation Bio
NYSE
Loading...
Adaptive
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Nuvation Bio wins in 8 metrics, Adaptive wins in 10 metrics, with 0 ties. Adaptive appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Nuvation Bio | Adaptive | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -1.49 | -11.68 | Adaptive |
| Price-to-Book Ratio | 2.88 | 10.68 | Nuvation Bio |
| Debt-to-Equity Ratio | 15.49 | 121.39 | Nuvation Bio |
| PEG Ratio | 0.02 | 0.26 | Nuvation Bio |
| EV/EBITDA | 2.61 | -18.87 | Adaptive |
| Profit Margin (TTM) | 10.10% | -59.07% | Nuvation Bio |
| Operating Margin (TTM) | -1,315.72% | -42.52% | Adaptive |
| Return on Equity | -44.84% | -57.60% | Nuvation Bio |
| Return on Assets (TTM) | 20.17% | -14.00% | Nuvation Bio |
| Free Cash Flow (TTM) | $-130.58M | $-98.88M | Adaptive |
| 1-Year Return | 2.95% | 173.54% | Adaptive |
| Price-to-Sales Ratio (TTM) | 74.87 | 9.36 | Adaptive |
| Enterprise Value | $524.78M | $1.94B | Adaptive |
| EV/Revenue Ratio | 36.56 | 9.45 | Adaptive |
| Gross Profit Margin (TTM) | 46.70% | 69.43% | Adaptive |
| Revenue per Share (TTM) | $0 | $1 | Adaptive |
| Earnings per Share (Diluted) | $-0.38 | $-0.81 | Nuvation Bio |
| Beta (Stock Volatility) | 1.37 | 1.94 | Nuvation Bio |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Nuvation Bio vs Adaptive Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Nuvation Bio | -6.27% | -19.49% | 35.34% | 73.48% | 40.18% | 21.24% |
| Adaptive | -6.52% | -1.87% | -0.39% | 21.13% | 65.49% | 103.72% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Nuvation Bio | 2.95% | 38.33% | -71.45% | -68.44% | -68.44% | -68.44% |
| Adaptive | 173.54% | 65.27% | -72.79% | -73.89% | -73.89% | -73.89% |
News Based Sentiment: Nuvation Bio vs Adaptive
Nuvation Bio
News based Sentiment: POSITIVE
Nuvation Bio demonstrated strong early commercial traction with IBTROZI™ in Q2 2025, coupled with active investor engagement and a potential financing deal for taletrectinib. While some analyst concerns exist, the overall narrative is positive, supported by insider buying and bullish market signals.
Adaptive
News based Sentiment: POSITIVE
Adaptive Biotechnologies is demonstrating strong growth, particularly in its MRD business, and is receiving positive attention from analysts. While some short-term volatility exists, the overall trend is positive, driven by upward earnings revisions and a favorable market outlook. The upcoming conference and earnings report will be key catalysts to watch.
Performance & Financial Health Analysis: Nuvation Bio vs Adaptive
| Metric | NUVB | ADPT |
|---|---|---|
| Market Information | ||
| Market Cap | $1.07B | $1.92B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 8,443,260 | 1,993,980 |
| 90 Day Avg. Volume | 6,001,997 | 2,153,267 |
| Last Close | $3.14 | $12.61 |
| 52 Week Range | $1.54 - $4.09 | $3.98 - $13.68 |
| % from 52W High | -23.23% | -7.82% |
| All-Time High | $15.23 (May 24, 2021) | $71.25 (Jan 18, 2021) |
| % from All-Time High | -79.38% | -82.30% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 2.37% | 0.36% |
| Quarterly Earnings Growth | 2.37% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | -0.59% |
| Operating Margin (TTM) | -13.16% | -0.43% |
| Return on Equity (TTM) | -0.45% | -0.58% |
| Debt to Equity (MRQ) | 15.49 | 121.39 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.09 | $1.18 |
| Cash per Share (MRQ) | $1.78 | $1.30 |
| Operating Cash Flow (TTM) | $-168,192,000 | $-80,470,000 |
| Levered Free Cash Flow (TTM) | $179.17M | $-18,756,124 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Nuvation Bio vs Adaptive
| Metric | NUVB | ADPT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -1.49 | -11.68 |
| Forward P/E | -4.98 | -13.41 |
| PEG Ratio | 0.02 | 0.26 |
| Price to Sales (TTM) | 74.87 | 9.36 |
| Price to Book (MRQ) | 2.88 | 10.68 |
| Market Capitalization | ||
| Market Capitalization | $1.07B | $1.92B |
| Enterprise Value | $524.78M | $1.94B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 36.56 | 9.45 |
| Enterprise to EBITDA | 2.61 | -18.87 |
| Risk & Other Metrics | ||
| Beta | 1.37 | 1.94 |
| Book Value per Share (MRQ) | $1.09 | $1.18 |
Financial Statements Comparison: Nuvation Bio vs Adaptive
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NUVB | ADPT |
|---|---|---|
| Revenue/Sales | $4.83M | $52.44M |
| Cost of Goods Sold | $2.58M | $16.98M |
| Gross Profit | $2.26M | $35.46M |
| Research & Development | $27.36M | $24.20M |
| Operating Income (EBIT) | $-63.59M | $-29.60M |
| EBITDA | $-58.65M | $-22.19M |
| Pre-Tax Income | $-59.01M | $-29.83M |
| Income Tax | $0 | N/A |
| Net Income (Profit) | $-59.01M | $-29.83M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NUVB | ADPT |
|---|---|---|
| Cash & Equivalents | $47.98M | $50.65M |
| Total Current Assets | $475.57M | $256.49M |
| Total Current Liabilities | $52.77M | $87.81M |
| Long-Term Debt | $3.84M | $76.44M |
| Total Shareholders Equity | $419.46M | $190.22M |
| Retained Earnings | $-963.98M | $-1.33B |
| Property, Plant & Equipment | $1.53M | $88.43M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NUVB | ADPT |
|---|---|---|
| Operating Cash Flow | $-32.06M | $-18.25M |
| Capital Expenditures | $-72,000 | $-1.26M |
| Free Cash Flow | $-42.70M | $-29.74M |
| Debt Repayment | $-534,000 | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | NUVB | ADPT |
|---|---|---|
| Shares Short | 68.13M | 8.43M |
| Short Ratio | 15.08 | 3.96 |
| Short % of Float | 0.32% | 0.07% |
| Average Daily Volume (10 Day) | 8,443,260 | 1,993,980 |
| Average Daily Volume (90 Day) | 6,001,997 | 2,153,267 |
| Shares Outstanding | 337.84M | 147.77M |
| Float Shares | 231.05M | 117.37M |
| % Held by Insiders | 0.19% | 0.02% |
| % Held by Institutions | 0.67% | 0.98% |
Dividend Analysis & Yield Comparison: Nuvation Bio vs Adaptive
| Metric | NUVB | ADPT |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |